Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep 28;2(2):e000321.
doi: 10.1136/rmdopen-2016-000321. eCollection 2016.

Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities

Laura C Cappelli  1 , Ami A Shah  1 , Clifton O Bingham 3rd  1
Affiliations

Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities

Laura C Cappelli et al. RMD Open. .

Abstract

Immune checkpoint inhibitors (ICIs) are newly approved treatments for advanced malignancies that are increasing survival. The mechanism of these drugs, non-specifically activating T cells, also leads to immune-mediated damage of tissue or immune-related adverse events (IRAE). IRAEs with rheumatic phenotypes are increasingly being recognised. Inflammatory arthritis, sicca syndrome, inflammatory myopathy, vasculitis and lupus nephritis have been described as a result of ICIs. Use of ICIs will be expanding in the coming years for several reasons. ICIs will be used in earlier stage cancer, for more indications, and additional drugs will be approved. The rheumatologist plays a critical role in evaluating and treating these patients. The expertise of rheumatologists in evaluating rheumatic signs and symptoms and treating patients with immunosuppression are critical in ensuring the optimal outcomes for patients with rheumatic IRAE. Collaboration between oncology and rheumatology for clinical care and research will enhance understanding of these new disease entities.

Keywords: Arthritis; Autoimmune Diseases; T Cells; Treatment.

PubMed Disclaimer

References

    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–64. 10.1038/nrc3239 - DOI - PMC - PubMed
    1. Ansell SM, Lesokhin AM, Borrello I et al. . PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311–19. 10.1056/NEJMoa1411087 - DOI - PMC - PubMed
    1. Powles T, Eder JP, Fine GD et al. . MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558–62. 10.1038/nature13904 - DOI - PubMed
    1. Motzer RJ, Escudier B, McDermott DF et al. . Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803–13. 10.1056/NEJMoa1510665 - DOI - PMC - PubMed
    1. Brahmer J, Reckamp KL, Baas P et al. . Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123–35. 10.1056/NEJMoa1504627 - DOI - PMC - PubMed

LinkOut - more resources